Phoenix Biotech Acquisition Stock Current Valuation
| PBAXWDelisted Stock | 0.06 0.0001 0.16% |
Valuation analysis of Phoenix Biotech Acqu helps investors to measure Phoenix Biotech's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Phoenix Biotech's price fluctuation is very steady at this time. Calculation of the real value of Phoenix Biotech Acqu is based on 3 months time horizon. Increasing Phoenix Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Phoenix stock is determined by what a typical buyer is willing to pay for full or partial control of Phoenix Biotech Acquisition. Since Phoenix Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Phoenix Stock. However, Phoenix Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0611 | Real 0.0426 | Hype 0.06 |
The intrinsic value of Phoenix Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Phoenix Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Phoenix Biotech Acquisition helps investors to forecast how Phoenix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Phoenix Biotech more accurately as focusing exclusively on Phoenix Biotech's fundamentals will not take into account other important factors: Phoenix Biotech Acquisition Company Current Valuation Analysis
Phoenix Biotech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Phoenix Biotech Acquisition has a Current Valuation of 0.0. This is 100.0% lower than that of the Capital Markets sector and about the same as Financials (which currently averages 0.0) industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Phoenix Biotech Acquisition is currently under evaluation in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Financials industry is at this time estimated at about 0.0. Phoenix Biotech adds roughly 0.0 in current valuation claiming only tiny portion of equities under Financials industry.Phoenix Fundamentals
| Return On Asset | -0.0255 | |||
| Number Of Shares Shorted | 9.11 K | |||
| Net Income | (2.52 M) | |||
| Total Debt | 650 K | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (1.71 M) | |||
| Beta | 0.044 | |||
| Total Asset | 42.37 M | |||
| Retained Earnings | (10.76 M) | |||
| Working Capital | 11.62 M | |||
| Z Score | -0.03 | |||
| Net Asset | 42.37 M |
About Phoenix Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Phoenix Biotech Acquisition's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Phoenix Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Phoenix Biotech Acquisition based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in Phoenix Stock
If you are still planning to invest in Phoenix Biotech Acqu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Phoenix Biotech's history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |